Sanofi’s digital manufacturing facility in Framingham, US, has received the Facility of the Year Award in the Facility of the Future category from the International Society for Pharmaceutical Engineering, highlighting Sanofi as a game changer for the future.
The Framingham facility, which opened last October, is one of the first of its kind worldwide and puts Sanofi at the forefront of bio-manufacturing. The whole industrial process is digitalized and paperless, and is 80 times more productive than a traditional factory. It can make medicines in less time for twice the number of patients and all within a smaller environmental footprint.
“The Framingham facility is a lighthouse in Sanofi’s strategic transformation of its global manufacturing platform,” said Brendan O’Callaghan, Global Head of Biologics at Sanofi. “This facility allows us to connect great science, differentiated medicines and the best in cutting edge, digitally-enabled manufacturing technologies.”
Factory of the Future at Sanofi
Sanofi’s $400 million (approx. €364 million) investment in Research and Development, biologics manufacturing and production improvements means all manufacturing stages are controlled through state-of-the-art analytical techniques that forecast and avoid variations to improve performance and ensure quality. Plant operators are supported by digital collaboration, data analytics or augmented reality solutions, helping them to make real-time decisions and adjustments, while simulations provide the level of manufacturing modularity and flexibility required to support personalized medicines.
Reducing Environmental Impact, Investing in the Future
Framingham’s smaller footprint significantly reduces the impact on the environment and the new technology results in less CO2 emissions.